|
|
|
| Protective effect of different doses of recombinant human interferon on central nervous system of children with severe hand-foot-mouth disease#br# |
| SONG Mingmei1 SUN Zhiwei1 LU Jiayun2▲ |
1.Department of Pediatrics, Wuxi Fifth People’s Hospital, Jiangsu Province, Wuxi 214044, China;
2.Department of Pharmacy, the 904th Hospital of Joint Logistic Support Force of Chinese People’s Liberation Army, Jiangsu Province, Wuxi 214044, China |
|
|
|
Abstract Objective To explore the protective effect of different doses of recombinant human interferon (hIFN) on central nervous system of children with severe hand foot mouth disease (HFMD). Methods The clinical data of 82 children with severe HFMD admitted to the 904th Hospital of the People’s Liberation Army Joint Logistic Support Force were retrospectively analyzed from March 2015 to October 2019. According to the treatment methods, they were divided into group A (conventional antiviral therapy, 20 cases), group B (2 μg/kg hIFN-α16 combined with conventional antiviral therapy, 31 cases), and group C (4 μg/kg hIFN-α16 combined with conventional antiviral therapy, 31 cases). The clinical symptoms, efficacy, immune function, and serological indexes of three groups were compared, and the incidence of adverse reactions during treatment were recorded. Results The time of rash resolution and fever resolution in group C were shorter than those in group A and B, and the time of rash resolution and fever resolution in group B were shorter than those in group A, and the differences were statistically significant (P ＜ 0.05). The total effective rate of group B and C were higher than those of group A, and the differences were statistically significant (P ＜ 0.05); there was no significant difference in total effective rate between group B and group C (P > 0.05). After treatment, CD3+ and CD4+ in three groups were higher than before treatment, group C was higher than group A and B, and group B was higher than group A, and the differences were statistically significant (P < 0.05); CD8+ in three groups were lower than before treatment, group C was lower than group A and B, and group B was lower than group A, and the differences were statistically significant (P < 0.05). After treatment, CRP, NSE, and S-100P levels in three groups were lower than those before treatment, and group C was lower than group A and B, and group B was lower than group A, and the differences were statistically significant (P < 0.05). Conclusion High-dose hIFN can significantly improve the clinical symptoms and immune function of children with severe HFMD, and has more significant protection on the central nervous system, with good safety.
|
|
|
|
|
|
[1] 王燕芬，王旭峰，赵继军，等.中国各省、自治区与直辖市手足口病传染率分析[J].复杂系统与复杂性科学，2019， 16（3）：79-86.
[2] 金玉晶，韩雪，葛国岚.针刺治疗儿童重症手足口病合并吞咽障碍疗效观察[J].中国针灸，2020，40（4）：391-394.
[3] 邓慧玲，张玉凤，宋鹤，等.维生素A、维生素D水平与柯萨奇病毒A6型手足口病重症化的关联性研究[J].中华实用儿科临床杂志，2020，35（18）：1394-1397.
[4] 中华人民共和国国家卫生健康委员会.手足口病诊疗指南（2018年版）[J].中华临床感染病杂志，2018，11（3）：161-166.
[5] 申天甜，高向东，蒋荣猛.重组人干扰素α1b注射液与利巴韦林治疗手足口病疗效和安全性的系统评价[J].儿科药学杂志，2018，24（5）：8-12.
[6] 闵晓兰，蔡强，卢玉容.重组人干扰素α-1b联合大剂量丙种球蛋白治疗重症手足口病合并病毒性脑炎的疗效[J].安徽医学，2019，40（4）：392-395.
[7] 陈敏，乐汉娥，冯静.热毒宁注射液治疗肠道病毒71型感染重症手足口病的临床研究[J].中华医院感染学杂志，2014，24（17）：4231-4233.
[8] 中华人民共和国卫生部.手足口病诊疗指南（2010年版）[J].国际呼吸杂志，2010，30（24）：1473-1475.
[9] 刘社兰，林君芬，张静.WHO手足口病临床管理与公共卫生应对指南第五部分临床特征及病例管理[J].疾病监测，2013，5（9）：784-788.
[10] 徐晓珍，黄敏，王彩兰.重症早期预警护理模式在手足口病患儿中的临床应用效果[J].临床与病理杂志，2020， 40（8）：2143-2148.
[11] 王杨，李祎，彭传梅，等.临床手足口病肠道病毒71型VP1基因分析[J].中国实验诊断学，2018，22（5）：811-814.
[12] 张文良，甘海忠，吴飞，等.肠道病毒71型感染手足口病患儿Th1/Th2细胞因子变化[J].中华医院感染学杂志，2020，30（7）：109-112.
[13] 庄帝钱，梁翠琼，赵芳，等.人肠道病毒71型感染致重症手足口病的危险因素分析[J].中国热带医学，2019， 19（4）：373-376.
[14] 侯云德，张国成.重视重组人干扰素α1b的创新研究和儿科临床应用[J].中华实用儿科临床杂志，2018，33（18）：1361-1365.
[15] 陈海哨，陈雪夏，周俊，等.重组人干扰素α-2b喷雾剂对手足口病患儿免疫功能的影响[J].中华医院感染学杂志，2019，29（10）：1562-1566.
[16] 申昆玲，张国成，尚云晓，等.重组人干扰素-α1b在儿科的临床应用专家共识[J].中华实用儿科临床杂志，2015， 30（16）：1214-1219.
[17] 蔡丽云，姚敏，王永卿，等.重组人干扰素α1b注射液联合阿糖腺苷注射剂治疗手足口病的临床研究[J].中国临床药理学杂志，2018，10（19）：2287-2290.
[18] 王凯，孔慧霞，刘静炎，等.重组人干扰素α-2b喷雾剂联合热毒宁治疗小儿手足口病的疗效分析[J].中华全科医学，2020，18（4）：561-563.
[19] 刘鲁闽.重组人干扰素α-2b雾化吸入治疗小儿手足口病的临床效果研究[J].中国医药导刊，2019，21（7）：413-416.
[20] 韩美园，廖震.重组人干扰素α-2b对重症手足口病患者的影响[J].中国妇幼健康研究，2020，31（6）：785-789.
[21] 何勤、蓝灵利、侯国祯.干扰素，炎琥宁联合舒咽清喷雾剂治疗小儿手足口病的疗效观察[J].中国预防医学杂志，2020，21（5）：102-105.
[22] 刘新生，李时光，王昆，等.NSE，S100蛋白及PCT在寻常脑炎中的鉴别价值[J].中华全科医学，2020，18（1）：37-40.
[23] 白春峰，管敏仓，吕静，等.病毒性脑炎患者神经功能指标和sICAM-1分析[J].中华医院感染学杂志，2019，29（19）：2943-2947.
[24] 庞文箫，刘勇，曾义岚，等.NSE，S-100β水平在重型手足口病中的变化及意义[J].中国妇幼健康研究，2019， 30（6）：106-109.
[25] 海元平，崔兰，李虹艾，等.手足口病患儿血清神经元特异性烯醇化酶及儿茶酚胺水平的临床意义[J].中国儿童保健杂志，2018，26（2）：196-198. |
|
|
|
